NCT02639559View on ClinicalTrials.gov

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

April 12, 2018

Study Completion Date

April 7, 2023

Conditions
Acute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous LeukemiaNon-Hodgkin's LymphomaNon-Hodgkin LymphomaHodgkin DiseaseHodgkins DiseaseHodgkin's DiseaseMultiple MyelomaMyelodysplastic SyndromeMyeloproliferative Neoplasm
Interventions
DRUG

BL-8040

PROCEDURE

Leukapheresis

PROCEDURE

Hematopoietic cell transplant

Trial Locations (3)

30342

Northside Hospital Cancer Institute, Atlanta

43210

Ohio State University, Columbus

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

BioLineRx, Ltd.
All Listed Sponsors
collaborator

BioLineRx, Ltd.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT02639559 - Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | Biotech Hunter | Biotech Hunter